SCHEMBL296671

SCHEMBL296671

C=CCC(C)C=C(C)CO

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL346930 1.00 TRPA1 (0.38) TRPA1
SCHEMBL1287812 0.78
SCHEMBL8343222 0.78
SCHEMBL18425121 0.77 ALOX15 (0.39) TRPA1
SCHEMBL14060452 0.77 ALOX15 (0.39) TRPA1
SCHEMBL14060451 0.77 ALOX15 (0.39) TRPA1
SCHEMBL14146580 0.77 ALOX15 (0.39) TRPA1
SCHEMBL566898 0.76
SCHEMBL566899 0.76
SCHEMBL29216379 0.76 TRPA1 (0.37) TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230100363-A1 MOLECULARLY IMPRINTED POLYMERS FOR EXTRACTION OF CANNABINOIDS AND USES THEREOF ORCA HOLDINGS, LLC 2023-03-30 US claimed
US-20220177666-A1 MOLECULARLY IMPRINTED POLYMERS FOR EXTRACTION OF CANNABINOIDS AND USES THEREOF ORCA HOLDINGS, LLC 2022-06-09 US claimed
WO-2021050786-A1 CANNABIN OID COMPOSITIONS WITH IMPROVED ORGANOLEPTIC AND THERAPEUTIC PROPERTIES, METHOD OF PRODUCTION, AND USE THEREOF CALIFORNIA AMBER INC. (US) 2021-03-18 WO claimed
US-20210068444-A1 CANNABINOID COMPOSITIONS WITH IMPROVED ORGANOLEPTIC AND THERAPEUTIC PROPERTIES, METHOD OF PRODUCTION, AND USE THEREOF CALIFORNIA AMBER INC. 2021-03-11 US claimed
US-8603962-B2 Methods for treating fabric in a dryer with a composition comprising silicic acid esters THE DIAL CORPORATION (US) 2013-12-10 US claimed
EP-2142631-B1 METHODS FOR TREATING FABRIC IN A DRYER DIAL CORP (US) 2012-03-14 EP claimed
US-20100212181-A1 METHODS FOR TREATING FABRIC IN A DRYER THE DIAL CORPORATION (US) 2010-08-26 US claimed
US-7678870-B2 Processable molecularly imprinted polymers THE JOHNS HOPKINS UNIVERSITY (US) 2010-03-16 US claimed
EP-2142631-A1 METHODS FOR TREATING FABRIC IN A DRYER The Dial Company (US) 2010-01-13 EP claimed
WO-2008134212-A1 METHODS FOR TREATING FABRIC IN A DRYER THE DIAL COMPANY (US) 2008-11-06 WO claimed
US-20070197746-A1 Processable molecularly imprinted polymers THE JOHNS HOPKINS UNIVERSITY 2007-08-23 US claimed
EP-1733211-A4 PROCESSABLE MOLECULARLY IMPRINTED POLYMERS UNIV JOHNS HOPKINS (US) 2007-05-30 EP claimed
EP-1733211-A1 PROCESSABLE MOLECULARLY IMPRINTED POLYMERS THE JOHNS-HOPKINS UNIVERSITY (US) 2006-12-20 EP claimed
WO-2005103655-A1 PROCESSABLE MOLECULARLY IMPRINTED POLYMERS THE JOHNS HOPKINS UNIVERSITY (US) 2005-11-03 WO claimed
EP-1509302-A1 SOLID MYCOCTOXIN CARRIERS Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung (AT) 2005-03-02 EP claimed
WO-2003101580-A1 SOLID MYCOCTOXIN CARRIERS Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung (AT) 2003-12-11 WO claimed
EP-1056739-B1 NOVEL CYCLIC PRO-PERFUMES HAVING MODIFIABLE FRAGRANCE RAW MATERIAL ALCOHOL RELEASE RATE PROCTER & GAMBLE (US) 2003-05-02 EP claimed
US-6500797-B1 Process for preparing β-ketoester fragrance pro-accords from 1,3-dioxan-4,6-diones THE PROCTER & GAMBLE COMPANY 2002-12-31 US claimed
EP-0037584-B1 2,4-DIALKYL-2,6-HEPTADIENALS AND -HETADIENOLS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PERFUME COMPOUNDS AND FLAVOURINGS Consortium für elektrochemische Industrie GmbH (DE) 1983-11-16 EP claimed
US-4380675-A 2,4-Dialkyl-2,6-heptadienal derivatives, a process for their preparation, and fragrant and flavoring products made therewith CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) 1983-04-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230100363-A1 MOLECULARLY IMPRINTED POLYMERS FOR EXTRACTION OF CANNABINOIDS AND USES THEREOF CNR2, CNR1, CDIPT TRPA1 2636/4885
US-20220177666-A1 MOLECULARLY IMPRINTED POLYMERS FOR EXTRACTION OF CANNABINOIDS AND USES THEREOF CNR2, CNR1, CDIPT TRPA1 2636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.